Login to Your Account



Alexion's Heart Drug Fizzles In Second Phase III CABG Study

By Randall Osborne


Monday, November 28, 2005
Bad pre-holiday news from the Phase III trial with pexelizumab gave investors in Alexion Pharmaceuticals Inc. little cause to be thankful, and Wall Street took away more than a fourth of the stock's value. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription